Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/MDMA/Immunology & Inflammation

MDMA for Immunology & Inflammation

5 papers and 0 clinical trials exploring mdma as a treatment for immunology & inflammation.

Compoundempathogen

MDMA

MDMA is a synthetic empathogen that enhances monoamine release, producing prosocial and anxiolytic effects without frank hallucinosis. Two Phase III trials demonstrated significant PTSD symptom reductions, though FDA review raised concerns about blinding, durability, and safety characterisation.

Full MDMA profile
IndicationOver 264 million people worldwide suffer from depression, with a significant subset experiencing related inflammatory conditions.

Immunology & Inflammation

Recent research highlights the potential of psychedelics, particularly psilocybin and MDMA, in modulating immune responses and inflammation, shedding light on their therapeutic implications for mood disorders and other immune-related conditions. Studies are beginning to uncover the mechanisms through which these compounds exert anti-inflammatory effects and promote neuroplasticity, particularly in the context of major depressive disorder (MDD).

Full Immunology & Inflammation profile

Academic Research

5 papers
Open Accessindividual

Inflammatory biomarker outcomes associated with MDMA-assisted therapy: an open-label exploratory study

This open-label exploratory study (n=23) examined inflammatory biomarkers in Veterans with PTSD during MDMA-assisted group therapy and found small changes in interleukin-6, tumour necrosis factor alpha and C-reactive protein. Higher baseline inflammation was linked with worse PTSD symptoms, and changes in interleukin-6 were related to symptom improvement.

Published
March 23, 2026
Journal
Frontiers in Neuroscience
Authors
Kachmarik, J. E., Loftis, J. M., Stauffer, C. S.
Open Accessindividual

Methylone is a rapid-acting neuroplastogen with less off-target activity than MDMA

Using in vitro receptor profiling and rat RNA‑seq, the authors show methylone is a monoamine uptake inhibitor/releaser that rapidly upregulates neuroplasticity‑related genes in frontal cortex and regulates myelin‑related genes in the amygdala. Unlike MDMA, methylone showed no off‑target activity across 168 GPCRs, indicating greater specificity and supporting its potential as a PTSD treatment.

Published
February 7, 2024
Journal
Frontiers in Neuroscience
Authors
Schmidt, E. F., Warner-Schmidt, J., Stogniew, M., Mandell, B., Rowland, R. S., Kelmendi, B.
Open Accessindividual

Oxytocin in response to MDMA provocation test in patients with arginine vasopressin deficiency (central diabetes insipidus): a single-centre, case-control study with nested, randomised, double-blind, placebo-controlled crossover trial

This double-blind, placebo-controlled study (n=30) explores oxytocin deficiency in patients with arginine vasopressin deficiency (central diabetes insipidus), using MDMA as a biochemical and psychoactive provocation test. The participants included patients with vasopressin deficiency and healthy controls, who were given either MDMA or placebo in a randomised order over two sessions.

Published
July 1, 2023
Journal
Lancet Diabetes Endocrinol
Authors
Atila, C., Christ-Crain, M., Liechti, M. E., Holze, F., Murugesu, R., Phd, R., Hutter, N., Sailer, C. O., Heinrichs, M., Rommers, N., Varghese, N., Eckert, A.
Open Accessmeta

MDMA related neuro-inflammation and adenosine receptors

This review (2022) explores the cellular mechanisms involved in MDMA neuroinflammatory effects. The protective effects of adenosine receptors is also discussed.

Published
January 3, 2022
Journal
Neurochemistry International
Authors
Kermanian, F., Seghatoleslam, M., Mahakizadeh, S.
Open Accessmeta

Psychedelics

This paper is the most comprehensive review of psychedelics research up to 2016 by the eminent David E. Nichols.

Published
April 1, 2016
Journal
Pharmacological Reviews
Authors
Nichols, D. E.

Clinical Trials

0 trials

No clinical trials have been tagged with both MDMA and Immunology & Inflammation yet.

Trials are continuously being added as new studies are registered.

Explore further

Search all MDMA papers Search all Immunology & Inflammation trials Full MDMA profile Full Immunology & Inflammation profile